Inhibikase Therapeutics, Inc. (IKT) News
Track canonical SquawkNews coverage tagged to IKT, Inhibikase Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Inhibikase Therapeutics (NASDAQ: IKT ) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
EARNINGS | Aug 11, 2026, 08:16 PM UTC
L
IKT - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
IKT - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
EARNINGS | Aug 11, 2026, 08:01 PM UTC
L
IKT Inhibikase Therapeutics announces FDA orphan drug designation granted to ikt-001 for the treatment of pah
IKT Inhibikase Therapeutics announces FDA orphan drug designation granted to ikt-001 for the treatment of pah
REGULATION | Jul 23, 2026, 12:00 PM UTC
H
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday. Shares of Danaher Corp (NYSE: DHR ) fell sharply in pre-market trading following second-quarter results. Danaher p
EARNINGS | Jul 21, 2026, 12:01 PM UTC
L
Inhibikase Therapeutics' treatment of PAH granted FDA orphan designation
Inhibikase...
REGULATION | Jul 16, 2026, 09:03 PM UTC